Mapping the Pareto Optimal Design Space for a Functionally Deimmunized Biotherapeutic Candidate

Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate

(2014) Regina S. Salvat et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

What's fueling the biotech engine—2012 to 2013

(2014) Saurabh (Rob) Aggarwal   NATURE BIOTECHNOLOGY

Evaluating the Immunogenicity of Protein Drugs by ApplyingIn VitroMHC Binding Data and the Immune Epitope Database and Analysis Resource

(2013) Sinu Paul et al.   Clinical & Developmental Immunology

Structure-Guided Deimmunization of Therapeutic Proteins

(2013) Andrew S. Parker et al.   JOURNAL OF COMPUTATIONAL BIOLOGY

Biologic drugs set to top 2012 sales

(2012)   NATURE MEDICINE

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A

(2012) R. Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design and analysis of immune-evading enzymes for ADEPT therapy

(2012) D. C. Osipovitch et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo

(2011) Leonard Moise et al.   CLINICAL IMMUNOLOGY

Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters

(2011) Maria D.F.S. Barbosa   DRUG DISCOVERY TODAY

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

(2011) J. R. Cantor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments

(2011) Lu He et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

OPTIMIZATION OF THERAPEUTIC PROTEINS TO DELETE T-CELL EPITOPES WHILE MAINTAINING BENEFICIAL RESIDUE INTERACTIONS

(2011) ANDREW S. PARKER et al.   Journal of Bioinformatics and Computational Biology

Optimization algorithms for functional deimmunization of therapeutic proteins

(2010) Andrew S Parker et al.   BMC BIOINFORMATICS

Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics

(2009) Anne S. De Groot et al.   CLINICAL IMMUNOLOGY

Reducing the Immunogenicity of Protein Therapeutics

(2009) Masanori Onda   CURRENT DRUG TARGETS

Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin

(2009) Jeannick Cizeau et al.   JOURNAL OF IMMUNOTHERAPY

In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes

(2009) Leonard Moise et al.   VACCINE

New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development

(2008) Laura C A Perry et al.   Drugs in research & development

A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach

(2008) Peng Wang et al.   PLoS Computational Biology